# A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

> **NCT01617941** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening

## Interventions

- **DRUG:** BGG492
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01617941
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-05
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617941, "A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01617941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*